Morgan Stanley
ALDX icon

Morgan Stanley’s Aldeyra Therapeutics ALDX Stock Holding History

Morgan Stanley’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$877K Sell
518,642
-138,390
-21% -$606K ﹤0.01% 5216
2025
Q4 		$3.4M Sell
657,032
-426,287
-39% -$2.19M ﹤0.01% 4456
2025
Q3 		$5.65M Buy
1,083,319
+308,283
+40% +$1.61M ﹤0.01% 4053
2025
Q2 		$2.97M Buy
775,036
+219,977
+40% +$569K ﹤0.01% 4453
2025
Q1 		$3.19M Sell
555,059
-24,656
-4% -$146K ﹤0.01% 4287
2024
Q4 		$2.89M Buy
579,715
+59,069
+11% +$303K ﹤0.01% 4431
2024
Q3 		$2.81M Buy
520,646
+209,242
+67% +$996K ﹤0.01% 4414
2024
Q2 		$1.03M Sell
311,404
-38,142
-11% -$149K ﹤0.01% 4945
2024
Q1 		$1.14M Sell
349,546
-490,590
-58% -$1.61M ﹤0.01% 4889
2023
Q4 		$2.95M Buy
840,136
+591,021
+237% +$1.82M ﹤0.01% 4727
2023
Q3 		$1.66M Sell
249,115
-71,913
-22% -$534K ﹤0.01% 4504
2023
Q2 		$2.69M Sell
321,028
-858,935
-73% -$8.46M ﹤0.01% 4225
2023
Q1 		$11.7M Buy
1,179,963
+864,713
+274% +$6.11M ﹤0.01% 2994
2022
Q4 		$2.19M Buy
315,250
+12,607
+4% +$72.1K ﹤0.01% 4398
2022
Q3 		$1.62M Sell
302,643
-62,317
-17% -$374K ﹤0.01% 4578
2022
Q2 		$1.46M Buy
364,960
+11,810
+3% +$40.6K ﹤0.01% 4760
2022
Q1 		$1.57M Buy
353,150
+179,946
+104% +$717K ﹤0.01% 4686
2021
Q4 		$693K Buy
173,204
+118,084
+214% +$901K ﹤0.01% 5343
2021
Q3 		$483K Sell
55,120
-36,627
-40% -$336K ﹤0.01% 5519
2021
Q2 		$1.04M Buy
91,747
+75,372
+460% +$906K ﹤0.01% 5052
2021
Q1 		$194K Buy
16,375
+3,680
+29% +$42.4K ﹤0.01% 5673
2020
Q4 		$87K Buy
12,695
+7,295
+135% +$51.2K ﹤0.01% 5965
2020
Q3 		$40K Sell
5,400
-212,366
-98% -$1.37M ﹤0.01% 5798
2020
Q2 		$908K Buy
217,766
+215,879
+11,440% +$789K ﹤0.01% 4245
2020
Q1 		$4K Sell
1,887
-30,989
-94% -$139K ﹤0.01% 6256
2019
Q4 		$191K Buy
32,876
+23,493
+250% +$136K ﹤0.01% 5432
2019
Q3 		$50K Buy
9,383
+7,114
+314% +$38.3K ﹤0.01% 5718
2019
Q2 		$14K Sell
2,269
-3,570
-61% -$26.9K ﹤0.01% 6036
2019
Q1 		$53K Sell
5,839
-27,778
-83% -$236K ﹤0.01% 5642
2018
Q4 		$279K Sell
33,617
-2,609
-7% -$26.7K ﹤0.01% 5141
2018
Q3 		$500K Sell
36,226
-6,546
-15% -$53.1K ﹤0.01% 5001
2018
Q2 		$340K Buy
42,772
+27,976
+189% +$223K ﹤0.01% 5309
2018
Q1 		$111K Buy
14,796
+4,686
+46% +$35.6K ﹤0.01% 5676
2017
Q4 		$69K Buy
10,110
+327
+3% +$2.15K ﹤0.01% 5738
2017
Q3 		$71K Buy
9,783
+6,987
+250% +$36.5K ﹤0.01% 5671
2017
Q2 		$13K Buy
2,796
+3
+0.1% +$14 ﹤0.01% 6178
2017
Q1 		$14K Sell
2,793
-189
-6% -$973 ﹤0.01% 6162
2016
Q4 		$16K Sell
2,982
-1,478
-33% -$8.67K ﹤0.01% 6047
2016
Q3 		$35K Buy
4,460
+573
+15% +$3.5K ﹤0.01% 5728
2016
Q2 		$22K Buy
3,887
+298
+8% +$1.67K ﹤0.01% 5812
2016
Q1 		$15K Sell
3,589
-3,633
-50% -$17.5K ﹤0.01% 6017
2015
Q4 		$49K Sell
7,222
-13,274
-65% -$89.2K ﹤0.01% 5721
2015
Q3 		$119K Buy
20,496
+3,992
+24% +$31.2K ﹤0.01% 5339
2015
Q2 		$128K Buy
16,504
+2,663
+19% +$23K ﹤0.01% 5458
2015
Q1 		$141K Buy
13,841
+12,541
+965% +$128K ﹤0.01% 5378
2014
Q4 		$9K Buy
+1,300
New +$9.32K ﹤0.01% 6232
2014
Q3 		– Sell
-9
Closed – – 6560
2014
Q2 		$0 Buy
+9
New +$60 ﹤0.01% 6506

Other funds holding ALDX

KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
KCM
Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Morgan Stanley's ALDX Position: Q1 2026 in Review

Morgan Stanley reduced its Aldeyra Therapeutics (ALDX) stake by 21% in Q1 2026, selling an estimated $606K and leaving 518,642 shares worth $877K. The position accounts for ﹤0.01% of the portfolio, ranked #5216.

Morgan Stanley first reported a position in ALDX in Q2 2014 and has held it in 47 quarters since. The position peaked at $11.7M in Q1 2023. 126 funds tracked by Wall St. Rank hold ALDX as of Q1 2026.

  • Morgan Stanley held 518,642 shares of Aldeyra Therapeutics worth $877K as of Q1 2026.
  • Morgan Stanley sold 138,390 Aldeyra Therapeutics shares in Q1 2026, an estimated $606K.
  • Aldeyra Therapeutics made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #5216 holding.
  • Morgan Stanley first reported a position in Aldeyra Therapeutics in Q2 2014 and has held it in 47 quarters since.
  • Morgan Stanley's Aldeyra Therapeutics position peaked at $11.7M in Q1 2023.
  • 126 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2026.

Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.